On October 24, 2024, CEO Antony Koblish purchased 88,888 shares of TELA Bio Inc (TELA, Financial), as reported in a recent SEC Filing. Following this transaction, the insider now owns a total of 458,897 shares in the company.
TELA Bio Inc is a company that specializes in the development and marketing of a broad range of implantable soft tissue reconstruction solutions. These products are used to address the needs in the repair of soft tissue injuries.
Over the past year, Antony Koblish has been actively increasing his stake in the company, with a total of 99,888 shares purchased and no shares sold. This latest acquisition is part of a broader trend of insider buying at TELA Bio Inc, with 7 insider buys recorded over the past year compared to just 1 insider sell.
Shares of TELA Bio Inc were priced at $2.25 on the day of the transaction. The company currently holds a market cap of approximately $63.763 million.
According to the GF Value, the intrinsic value of TELA Bio Inc is estimated at $10.56 per share, suggesting that the stock is currently undervalued with a price-to-GF-Value ratio of 0.21. This valuation indicates that the stock might be a Possible Value Trap, and investors should think twice before making an investment.
The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This insider buying activity could be a signal to investors about the potential undervaluation or future prospects of TELA Bio Inc, as perceived by the insider.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
